Feeds:
Posts
Comments

Archive for the ‘Artificial Intelligence Applications in Health Care’ Category


re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. 

 

Preview the tracks that will be available, along with the general agenda, on the website. 

 

https://reinvent.awsevents.com/

 

https://virtual.awsevents.com/agenda

 

awsreinvent-support@amazon.com

AWS re:Invent 2020 – Life Sciences Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. Hear how AWS experts and inspiring members of the Life Sciences & Genomics industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Life Sciences attendees looking to get the most out of their experience, follow these steps:

  • Register for re:Invent.
  • Take a look at all of the Life Sciences sessions available, as well as lots of other information and additional activities, in our curated Life Sciences Attendee Guide coming soon!
  • Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Life Sciences at re:Invent 2020

AWS enables pharma and biotech companies to transform every stage of the pharma value chain, with services that enhance data liquidity, operational excellence, and customer engagement. AWS is the trusted technology provider with the cost-effective compute and storage, machine learning capabilities, and customer-centric know how to help companies embrace innovation and bring differentiated therapeutics to market faster.

Dates and Presentation Title

BlockChain Architecture

DEC 1, 2020 | 12:00 AM – 12:20 AM EST
Nestlé brings supply chain transparency with Amazon Managed Blockchain
Chain of origin is the Nestlé answer to complete supply chain transparency, from crop to coffee cup, with technology at its heart. Today, consumers want to know about the quality of their product and know where it is sourced from. Using AWS and Amazon Man

… Learn More

Add To Calendar
Blockchain Retail

Nestlé brings supply chain transparency with Amazon Managed Blockchain

Thursday, December 10
DEC 10, 2020 | 3:15 PM – 3:45 PM EST
Trust and transparency in live virtual events
This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.
Add To Calendar
Architecture Blockchain

Trust and transparency in live virtual events

DEC 10, 2020 | 11:15 PM – 11:45 PM EST
Trust and transparency in live virtual events
This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.
Add To Calendar
Architecture Blockchain

Trust and transparency in live virtual events

Friday, December 11
DEC 11, 2020 | 7:15 AM – 7:45 AM EST
Trust and transparency in live virtual events
This session demonstrates how to build interactive, trusted, and transparent live virtual experiences using the Amazon Interactive Video Service, Amazon Chime, Amazon QLDB, and Amazon Managed Blockchain to capture cryptographic, immutable, and verifiable records of real-time audience interactions.
Add To Calendar
Architecture Blockchain

Trust and transparency in live virtual events

Tuesday, December 15
DEC 15, 2020 | 4:00 PM – 4:30 PM EST
What’s new in Amazon Managed Blockchain
Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar
Blockchain Financial Services

What’s new in Amazon Managed Blockchain

Wednesday, December 16
DEC 16, 2020 | 12:00 AM – 12:30 AM EST
What’s new in Amazon Managed Blockchain
Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar
Blockchain Financial Services

What’s new in Amazon Managed Blockchain

DEC 16, 2020 | 8:00 AM – 8:30 AM EST
What’s new in Amazon Managed Blockchain
Amazon Managed Blockchain is a fully managed service that makes it easy for you to create and manage scalable blockchain networks using popular open-source technologies. Blockchain technologies enable groups of organizations to securely transact and

… Learn More

Add To Calendar
Blockchain Financial Services

What’s new in Amazon Managed Blockchain

Life Science and Healthcare

DEC 1, 2020 | 12:00 AM – 12:20 AM EST
Building robots to help hospitals become safer and smarter
In hospitals and other healthcare venues, robots increasingly perform contactless delivery and autonomous maintenance services to reduce the risk of exposing patients and medical staff to harmful viruses and bacteria. In this session, see how Solaris JetBrain and M

… Learn More

Add To Calendar
Robotics IoT

Building robots to help hospitals become safer and smarter

华米基于AWS构建全球云上健康服务

Melhores práticas na construção de um data lake para a saúde

DEC 1, 2020 | 5:15 PM – 5:45 PM EST
Transform research environments with Service Workbench on AWS
Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.
Add To Calendar
Public Sector Healthcare

Transform research environments with Service Workbench on AWS

Wednesday, December 2
DEC 2, 2020 | 1:15 AM – 1:45 AM EST
Transform research environments with Service Workbench on AWS
Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.
Add To Calendar
Public Sector Healthcare

Transform research environments with Service Workbench on AWS

DEC 2, 2020 | 9:15 AM – 9:45 AM EST
Transform research environments with Service Workbench on AWS
Reenvison how research environments are spun up by reducing wait times from days to minutes. Service Workbench on AWS promotes repeatability, multi-institutional collaboration, and transparency in the research process. In this session, learn how Harvard Medical School is procuring and deploying domain-specific data, tools, and secure IT environments to accelerate research.
Add To Calendar
Public Sector Healthcare

Transform research environments with Service Workbench on AWS

DEC 2, 2020 | 11:00 AM – 11:30 AM EST
Reinventing medical imaging with machine learning on AWS
It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar
Public Sector Healthcare

Reinventing medical imaging with machine learning on AWS

DEC 2, 2020 | 2:45 PM – 3:15 PM EST
Making healthcare more personal with MetroPlus Health
COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar
Healthcare Public Sector

Making healthcare more personal with MetroPlus Health

DEC 2, 2020 | 4:15 PM – 4:45 PM EST
Securing protected health information and high-risk datasets
Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar
Healthcare Life Sciences

Securing protected health information and high-risk datasets

DEC 2, 2020 | 5:45 PM – 6:15 PM EST
ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 
In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More
Add To Calendar
Public Sector Partner Solutions for Business

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored by Intel)

DEC 2, 2020 | 6:30 PM – 7:00 PM EST
How Vyaire uses AWS analytics to scale ventilator production & save lives
When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar
Analytics Healthcare

How Vyaire uses AWS analytics to scale ventilator production & save lives

DEC 2, 2020 | 7:00 PM – 7:30 PM EST
Reinventing medical imaging with machine learning on AWS
It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar
Public Sector Healthcare

Reinventing medical imaging with machine learning on AWS

DEC 2, 2020 | 10:45 PM – 11:15 PM EST
Making healthcare more personal with MetroPlus Health
COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar
Healthcare Public Sector

Making healthcare more personal with MetroPlus Health

Thursday, December 3
DEC 3, 2020 | 12:15 AM – 12:45 AM EST
Securing protected health information and high-risk datasets
Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar
Healthcare Life Sciences

Securing protected health information and high-risk datasets

DEC 3, 2020 | 1:45 AM – 2:15 AM EST
ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 
In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More
Add To Calendar
Public Sector Partner Solutions for Business

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored by Intel)

DEC 3, 2020 | 2:30 AM – 3:00 AM EST
How Vyaire uses AWS analytics to scale ventilator production & save lives
When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar
Analytics Healthcare

How Vyaire uses AWS analytics to scale ventilator production & save lives

DEC 3, 2020 | 3:00 AM – 3:30 AM EST
Reinventing medical imaging with machine learning on AWS
It is hard to imagine the future of medical imaging without machine learning (ML) as its central innovation engine. Countless researchers, developers, startups, and larger enterprises are engaged in building, training, and deploying ML solutions for medical i

… Learn More

Add To Calendar
Public Sector Healthcare

Reinventing medical imaging with machine learning on AWS

DEC 3, 2020 | 6:45 AM – 7:15 AM EST
Making healthcare more personal with MetroPlus Health
COVID has made a huge impact across the world, and organizations have had to adapt quickly to changing requirements as a result. Learn how MetroPlus Health, a New York City health plan covering over half a million people, leveraged AWS technology to quickly

… Learn More

Add To Calendar
Healthcare Public Sector

Making healthcare more personal with MetroPlus Health

DEC 3, 2020 | 8:15 AM – 8:45 AM EST
Securing protected health information and high-risk datasets
Join this session featuring Jonathan Cook, Chief Technology Officer at Arcadia, for a discussion around securing mission-critical and high-risk datasets such as personal health information (PHI) in the cloud. Learn how Arcadia developed a HITRUST CSF-certified plat

… Learn More

Add To Calendar
Healthcare Life Sciences

Securing protected health information and high-risk datasets

DEC 3, 2020 | 9:45 AM – 10:15 AM EST
ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored … 
In this session, learn how Fractal.AI delivered a platform to help analyze data and make decisions related to COVID-19 progression for the government of Telangana, India, deploying it on AWS in five days. The solution, based on Intel processors, delivered more than 100 dashboards using anonymized government and public datasets with hundreds of thousands of COVID-19 d… Learn More
Add To Calendar
Public Sector Partner Solutions for Business

ML and analytics addressing nationwide COVID-19 impact and recovery (sponsored by Intel)

DEC 3, 2020 | 10:30 AM – 11:00 AM EST
How Vyaire uses AWS analytics to scale ventilator production & save lives
When COVID-19 hit the US, Vyaire Medical, one of the country’s only ventilator manufacturers, knew it would have to scale rapidly while still offering quality machinery. In order to scale to 20 times more than its usual production and gain insights from all its new

… Learn More

Add To Calendar
Analytics Healthcare

How Vyaire uses AWS analytics to scale ventilator production & save lives

DEC 3, 2020 | 4:15 PM – 4:45 PM EST
Productionizing R workloads using Amazon SageMaker, featuring Siemens
R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Enterprise/Migration

Productionizing R workloads using Amazon SageMaker, featuring Siemens

DEC 3, 2020 | 6:15 PM – 6:45 PM EST
Accelerating the transition to telehealth with AWS
Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar
Healthcare Public Sector

Accelerating the transition to telehealth with AWS

Friday, December 4
DEC 4, 2020 | 12:15 AM – 12:45 AM EST
Productionizing R workloads using Amazon SageMaker, featuring Siemens
R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Enterprise/Migration

Productionizing R workloads using Amazon SageMaker, featuring Siemens

DEC 4, 2020 | 2:15 AM – 2:45 AM EST
Accelerating the transition to telehealth with AWS
Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar
Healthcare Public Sector

Accelerating the transition to telehealth with AWS

DEC 4, 2020 | 8:15 AM – 8:45 AM EST
Productionizing R workloads using Amazon SageMaker, featuring Siemens
R language and its 16,000+ packages dedicated to statistics and ML are used by statisticians and data scientists in industries such as energy, healthcare, life science, and financial services. Using R, you can run simulations and ML securely and at scale with Amazon S

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Enterprise/Migration

Productionizing R workloads using Amazon SageMaker, featuring Siemens

DEC 4, 2020 | 10:15 AM – 10:45 AM EST
Accelerating the transition to telehealth with AWS
Learn how AWS is helping healthcare organizations develop and deploy telehealth solutions quickly and at scale. Join speakers from AWS and MedStar Health as they discuss their experience developing and deploying two call centers in less than a week using Amaz

… Learn More

Add To Calendar
Healthcare Public Sector

Accelerating the transition to telehealth with AWS

Tuesday, December 8
DEC 8, 2020 | 2:30 PM – 3:00 PM EST
How Erickson Living built a COVID-19 outbreak management solution
As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar
Analytics Life Sciences

How Erickson Living built a COVID-19 outbreak management solution

DEC 8, 2020 | 5:30 PM – 6:00 PM EST
Rapidly deploying social services on Amazon Connect
Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar
Public Sector Business Apps (including Connect)

Rapidly deploying social services on Amazon Connect

DEC 8, 2020 | 5:30 PM – 6:00 PM EST
Improving data liquidity in Roche’s personalized healthcare platform
Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar
Life Sciences Artificial Intelligence & Machine Learning

Improving data liquidity in Roche’s personalized healthcare platform

DEC 8, 2020 | 10:30 PM – 11:00 PM EST
How Erickson Living built a COVID-19 outbreak management solution
As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar
Analytics Life Sciences

How Erickson Living built a COVID-19 outbreak management solution

Wednesday, December 9
DEC 9, 2020 | 1:30 AM – 2:00 AM EST
Rapidly deploying social services on Amazon Connect
Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar
Public Sector Business Apps (including Connect)

Rapidly deploying social services on Amazon Connect

DEC 9, 2020 | 1:30 AM – 2:00 AM EST
Improving data liquidity in Roche’s personalized healthcare platform
Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar
Life Sciences Artificial Intelligence & Machine Learning

Improving data liquidity in Roche’s personalized healthcare platform

DEC 9, 2020 | 6:30 AM – 7:00 AM EST
How Erickson Living built a COVID-19 outbreak management solution
As innovators in independent living, assisted living, and skilled nursing care, Erickson Living responded to the COVID-19 outbreak by building an infectious disease management system with the AWS Data Lab to prevent the spread of the virus. This session focuses o

… Learn More

Add To Calendar
Analytics Life Sciences

How Erickson Living built a COVID-19 outbreak management solution

DEC 9, 2020 | 9:30 AM – 10:00 AM EST
Rapidly deploying social services on Amazon Connect
Organizations that respond to disruptive, large-scale events need the ability to rapidly scale and iterate on their contact centers to provide services to their constituents. Amazon Connect can be set up in minutes and scale to handle virtually any number of contact

… Learn More

Add To Calendar
Public Sector Business Apps (including Connect)

Rapidly deploying social services on Amazon Connect

DEC 9, 2020 | 9:30 AM – 10:00 AM EST
Improving data liquidity in Roche’s personalized healthcare platform
Roche’s personalized healthcare mission is to accelerate drug discovery and transform the patient journey by using digital technologies and advanced analytics to facilitate greater scientific collaboration and insight sharing. In this session, Roche shares ho

… Learn More

Add To Calendar
Life Sciences Artificial Intelligence & Machine Learning

Improving data liquidity in Roche’s personalized healthcare platform

DEC 9, 2020 | 10:30 AM – 11:00 AM EST
BlueJeans’ explosive growth journey with AWS during the pandemic
Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar
Telecommunications Media & Entertainment

BlueJeans’ explosive growth journey with AWS during the pandemic

DEC 9, 2020 | 5:15 PM – 5:45 PM EST
Using AI to automate clinical workflows
Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Using AI to automate clinical workflows

DEC 9, 2020 | 5:45 PM – 6:15 PM EST
Building patient-centric virtualized trials
As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar
Life Sciences Healthcare

Building patient-centric virtualized trials

DEC 9, 2020 | 6:30 PM – 7:00 PM EST
BlueJeans’ explosive growth journey with AWS during the pandemic
Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar
Telecommunications Media & Entertainment

BlueJeans’ explosive growth journey with AWS during the pandemic

Thursday, December 10
DEC 10, 2020 | 1:15 AM – 1:45 AM EST
Using AI to automate clinical workflows
Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Using AI to automate clinical workflows

DEC 10, 2020 | 1:45 AM – 2:15 AM EST
Building patient-centric virtualized trials
As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar
Life Sciences Healthcare

Building patient-centric virtualized trials

DEC 10, 2020 | 2:30 AM – 3:00 AM EST
BlueJeans’ explosive growth journey with AWS during the pandemic
Global video provider BlueJeans (a Verizon company) supports employees working from home, healthcare providers shifting to telehealth, and educators moving to distance learning. With so many people now working from home, BlueJeans saw explosive gro

… Learn More

Add To Calendar
Telecommunications Media & Entertainment

BlueJeans’ explosive growth journey with AWS during the pandemic

DEC 10, 2020 | 9:15 AM – 9:45 AM EST
Using AI to automate clinical workflows
Learn how healthcare organizations can harness the power of AI and machine learning to automate clinical workflows, digitize medical information, extract and summarize medical information, protect patient data, and more. Using AWS document understand

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Using AI to automate clinical workflows

DEC 10, 2020 | 9:45 AM – 10:15 AM EST
Building patient-centric virtualized trials
As clinical trials increasingly become decentralized and virtual, engaging effectively with patients can be challenging. In this session, hear how Evidation Health architects on AWS to create patient-centric experiences, ingests data from millions of devices in real time

… Learn More

Add To Calendar
Life Sciences Healthcare

Building patient-centric virtualized trials

DEC 10, 2020 | 2:30 PM – 3:00 PM EST
Edge computing innovation with AWS Snowcone and AWS Snowball Edge
In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More
Add To Calendar
Storage Business Apps (including Connect)

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

DEC 10, 2020 | 4:00 PM – 4:30 PM EST
Healthcare executive outlook: Accelerating transformation
Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is working

… Learn More

Add To Calendar
Healthcare Life Sciences

Healthcare executive outlook: Accelerating transformation

DEC 10, 2020 | 10:30 PM – 11:00 PM EST
Edge computing innovation with AWS Snowcone and AWS Snowball Edge
In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More
Add To Calendar
Storage Business Apps (including Connect)

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

Friday, December 11
DEC 11, 2020 | 12:00 AM – 12:30 AM EST
Healthcare executive outlook: Accelerating transformation
Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is worki

… Learn More

Add To Calendar
Healthcare Life Sciences

Healthcare executive outlook: Accelerating transformation

DEC 11, 2020 | 6:30 AM – 7:00 AM EST
Edge computing innovation with AWS Snowcone and AWS Snowball Edge
In this session, learn how the AWS Snow Family can help you run operations in harsh, non-data center environments and in locations where there is a lack of consistent network connectivity. The AWS Snow Family, comprised of AWS Snowcone and AWS Snowball Edge, offers a number of physical devices and capacity points with built-in computing capabilities. This sess… Learn More
Add To Calendar
Storage Business Apps (including Connect)

Edge computing innovation with AWS Snowcone and AWS Snowball Edge

DEC 11, 2020 | 8:00 AM – 8:30 AM EST
Healthcare executive outlook: Accelerating transformation
Join AWS Healthcare and Life Science Leader Shez Partovi, MD, for a look into how cloud technology can reshape the future of healthcare. In this executive overview, Dr. Partovi shares a vision of a digitally enhanced, data-driven future. Learn how AWS is worki

… Learn More

Add To Calendar
Healthcare Life Sciences

Healthcare executive outlook: Accelerating transformation

Tuesday, December 15
DEC 15, 2020 | 1:00 PM – 1:30 PM EST
Intelligent document processing for the insurance industry
Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Intelligent document processing for the insurance industry

DEC 15, 2020 | 3:00 PM – 3:30 PM EST
AWS Partners driving innovation amidst COVID-19
This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More
Add To Calendar
Global Partner Summit (GPS) Session

AWS Partners driving innovation amidst COVID-19

DEC 15, 2020 | 9:00 PM – 9:30 PM EST
Intelligent document processing for the insurance industry
Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Intelligent document processing for the insurance industry

DEC 15, 2020 | 11:00 PM – 11:30 PM EST
AWS Partners driving innovation amidst COVID-19
This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More
Add To Calendar
Global Partner Summit (GPS) Session

AWS Partners driving innovation amidst COVID-19

Wednesday, December 16
DEC 16, 2020 | 5:00 AM – 5:30 AM EST
Intelligent document processing for the insurance industry
Organizations in the insurance industry, both for healthcare and financial services, extract sensitive information such as names, dates, claims, or medical procedures from scanned images and documents to perform their business operations. These organization

… Learn More

Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Intelligent document processing for the insurance industry

DEC 16, 2020 | 7:00 AM – 7:30 AM EST
AWS Partners driving innovation amidst COVID-19
This session is open to anyone, but it is intended for current and potential AWS Partners. The COVID-19 pandemic has been a formative event affecting our world physically, emotionally, and economically. Despite the challenges created, AWS Partners have responded quickly and proven their resiliency by enabling digital transformation at unprecedented rates. In this sessi… Learn More
Add To Calendar
Global Partner Summit (GPS) Session

AWS Partners driving innovation amidst COVID-19

DEC 16, 2020 | 11:45 AM – 12:15 PM EST
Simplify healthcare compliance with third-party solutions
Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compli

… Learn More

Add To Calendar
Marketplace Healthcare

Simplify healthcare compliance with third-party solutions

DEC 16, 2020 | 12:45 PM – 1:15 PM EST
An introduction to healthcare interoperability and FHIR Works on AWS
Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar
Public Sector Healthcare

An introduction to healthcare interoperability and FHIR Works on AWS

DEC 16, 2020 | 1:15 PM – 1:45 PM EST
Achieving healthcare interoperability with FHIR Works on AWS
The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar
Public Sector Healthcare

Achieving healthcare interoperability with FHIR Works on AWS

DEC 16, 2020 | 6:00 PM – 6:30 PM EST
AWS at the edge: Using AWS IoT to optimize Amazon wind farms
AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar
IoT Manufacturing

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

DEC 16, 2020 | 7:45 PM – 8:15 PM EST
Simplify healthcare compliance with third-party solutions
Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compli

… Learn More

Add To Calendar
Marketplace Healthcare

Simplify healthcare compliance with third-party solutions

DEC 16, 2020 | 8:45 PM – 9:15 PM EST
An introduction to healthcare interoperability and FHIR Works on AWS
Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar
Public Sector Healthcare

An introduction to healthcare interoperability and FHIR Works on AWS

DEC 16, 2020 | 9:15 PM – 9:45 PM EST
Achieving healthcare interoperability with FHIR Works on AWS
The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar
Public Sector Healthcare

Achieving healthcare interoperability with FHIR Works on AWS

Thursday, December 17
DEC 17, 2020 | 2:00 AM – 2:30 AM EST
AWS at the edge: Using AWS IoT to optimize Amazon wind farms
AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar
IoT Manufacturing

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

DEC 17, 2020 | 3:45 AM – 4:15 AM EST
Simplify healthcare compliance with third-party solutions
Sensitive health data must be protected to ensure patient privacy, and healthcare organizations need to ensure that IT infrastructure is compliant with changing policies and regulations. In this session, learn how healthcare providers can address compliance

… Learn More

Add To Calendar
Marketplace Healthcare

Simplify healthcare compliance with third-party solutions

DEC 17, 2020 | 4:45 AM – 5:15 AM EST
An introduction to healthcare interoperability and FHIR Works on AWS
Fast Healthcare Interoperability Resources (FHIR) is gaining popularity around the world as the standard to use for exchanging healthcare data, and it is being increasingly adopted in Europe and Australasia. In the US, it is actually mandated in the 21st Century

… Learn More

Add To Calendar
Public Sector Healthcare

An introduction to healthcare interoperability and FHIR Works on AWS

DEC 17, 2020 | 5:15 AM – 5:45 AM EST
Achieving healthcare interoperability with FHIR Works on AWS
The Fast Healthcare Interoperability Resources (FHIR) standard has become increasingly necessary for enabling interoperability between healthcare applications and organizations. Join this session for a deep dive into how the FHIR Works on AWS open-source t

… Learn More

Add To Calendar
Public Sector Healthcare

Achieving healthcare interoperability with FHIR Works on AWS

DEC 17, 2020 | 10:00 AM – 10:30 AM EST
AWS at the edge: Using AWS IoT to optimize Amazon wind farms
AWS IoT and edge computing solutions move data processing and analysis closer to where data is generated to enable customers to innovate and achieve more sustainable operations. In this session, learn how Amazon renewable energy projects use AWS IoT to coll

… Learn More

Add To Calendar
IoT Manufacturing

AWS at the edge: Using AWS IoT to optimize Amazon wind farms

DEC 17, 2020 | 11:15 AM – 11:45 AM EST
Share information by removing language barriers with Amazon Translate
In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.
Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Share information by removing language barriers with Amazon Translate

DEC 17, 2020 | 7:15 PM – 7:45 PM EST
Share information by removing language barriers with Amazon Translate
In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.
Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Share information by removing language barriers with Amazon Translate

Friday, December 18
DEC 18, 2020 | 3:15 AM – 3:45 AM EST
Share information by removing language barriers with Amazon Translate
In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.
Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Share information by removing language barriers with Amazon Translate

Share information by removing language barriers with Amazon Translate
Friday, December 18
DEC 18, 2020 | 3:15 AM – 3:45 AM EST
Share information by removing language barriers with Amazon Translate
In this session, see how to use Amazon Translate and Amazon Transcribe to create subtitles for educational videos and translate them to the language of the consumer’s choice. The session includes a demonstration of how this process reduced the time it took for information about COVID-19 to be translated to many languages, thus spreading accurate information quickly.
Add To Calendar
Artificial Intelligence & Machine Learning Healthcare

Share information by removing language barriers with Amazon Translate

Life Sciences sessions

Bookmark this blog and check back for direct links to each session and add to your re:Invent schedule as soon as the session catalog is released:

LFS201: Life Sciences Industry: Executive Outlook
Learn how AWS technology is helping organizations improve their data liquidity, achieve operational excellence, and enhance customer engagement.

LFS202: Improving data liquidity in Roche’s personalized healthcare platform
Learn how Roche’s personalized healthcare platform is accelerating drug discovery and transforming the patient journey with digital technology.

LFS302: AstraZeneca genomics on AWS: from petabytes to new medicines
Learn how AstraZeneca built an industry leading genomics pipeline on AWS to analyze 2 million genomes in support of precision medicine.

LFS303: Building patient-centric virtualized trials
Learn how Evidation Health architects on AWS to create patient-centric experiences in decentralized and virtual clinical trials.

LFS304: Streamlining manufacturing and supply chain at Novartis
Learn how Novartis is creating real-time analytics and transparency in the pharma manufacturing process and supply chain to bring innovative medicines to market.

LFS305: Accelerating regulatory assessments in life sciences manufacturing
Learn how Merck leveraged Amazon Machine Learning to build an evaluation and recommendation engine for streamlining pharma manufacturing change requests.

Other related sessions of interest:

ENT203: How BMS automates GxP compliance for SAP systems on AWS

GPS211: AWS Partners driving innovation amidst COVID-19

HLC203: Securing Personal Health Information and High Risk Data Sets

WPS202: Transform research environments with Service Workbench on AWS

AIM310: Intelligent document processing for healthcare organizations

Healthcare Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned for the Healthcare industry with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. See how AWS experts and talented members of the Healthcare industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Healthcare attendees looking to get the most out of their experience, follow these steps:

  • Register for re:Invent.
  • Take a look at all of the Healthcare sessions available, as well as lots of other information and additional activities, in our curated Healthcare Attendee Guide coming soon!
  • Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Healthcare at re:Invent 2020

AWS is the trusted technology partner to the global healthcare industry. For over 12 years, AWS has established itself as the most mature, comprehensive, and broadly adopted cloud platform and is trusted by thousands of healthcare customers around the world—including the fastest-growing startups, the largest enterprises, and leading government agencies. The secure and compliant AWS technology enables the highly regulated healthcare industry to improve outcomes and lower costs by providing the tools to unlock the potential of healthcare data, predict healthcare events, and build closer relationships with patients and consumers. The healthcare track at re:Invent 2020 will feature customer-led sessions focused on these each of these critical components, accelerating the transformation of healthcare.

Healthcare sessions

Learn more and bookmark each Healthcare session:

HCL201: Healthcare Executive Outlook: Accelerating Transformation
Learn how AWS is working with industry leaders to increase their pace of innovation, unlock the potential of their healthcare data, help predict patient health events, and personalize the healthcare journey for their patients, consumers, and members.

HLC202: Making Healthcare More Personal with MetroPlus Health
Learn how MetroPlus Health leveraged AWS technology to quickly build and deploy an application that personally and proactively reached out to its members during a time of critical need.

HLC203: Securing Personal Health Information and High Risk Data Sets
Learn how Arcadia developed a HITRUST CSF Certified platform by leveraging AWS technology to enable the secure management of data from over 100 million patients.

HLC204: Accelerating the Transition to Virtual Care with AWS
Learn how MedStar Health developed and deployed two call centers in less than week that are supporting more than 3,500 outpatient telehealth sessions a day.

WPS202: Transform research environments with Service Workbench on AWS
Learn how Harvard Medical School is using AWS to procure and deploy domain-specific data, tools, and secure IT environments to accelerate research.

WPS209: Reinventing medical imaging with machine learning on AWS
Learn how Radboud University Medical Center uses AWS to power its machine learning imaging platform with 45,000+ registered researchers and clinicians from all over the world.

WPS211: An introduction to healthcare interoperability and FHIR Works on AWS
Learn about AWS FHIR Works, an open-source project, designed to accelerate the industries use of the interoperability standard, Fast Healthcare Interoperability Resources (FHIR).

WPS304: Achieving healthcare interoperability with FHIR Works on AWS
Learn how Black Pear Software leveraged AWS to build an integration toolkit to help their customers share healthcare data more effectively.

Extras you won’t want to miss out on!

LFS201: Life Sciences Industry: Executive outlook

LFS202: AstraZeneca genomics on AWS: From petabytes to new medicines

LFS303: Building patient-centric virtualized trials

AIM303: Using AI to automate clinical workflows

AIM310: Intelligent document processing for the insurance industry

INO204: Solving societal challenges with digital innovation on AWS

ZWL208: Using cloud-based genomic research to reduce health care disparities

GPS211: AWS Partners driving innovation amidst COVID-19

Read Full Post »


AI-controlled sensors could save lives in smart hospitals and homes

Reporter: Irina Robu, PhD

Arnold Milstein, professor of medicine and director of Stanford’s Clinical Excellence Research Center along with Fei-Fei Li, computer science professor and graduate student Albert Haque  believe that having the ability to build technologies into the physical spaces where health care is delivered minimize the rate of fatal errors that occur lately due to sheer volumes of patients and complexity of their care. Even though, the technology is a very promising, it also raises legal and regulatory issues as well as privacy concerns.

They believe that the AI can alert clinicians and patient visitors when they fail to sanitize their hands before entering hospital room for example. Also, AI tools can be built into smart homes where the technology can monitor the frail elderly for behavioral clues of a health crises and can let in-home caregivers, remotely located clinicians and patients to make life saving interventions.

Li and Milstein co-direct the 8-year-old Stanford Partnership in AI-Assisted Care (PAC), one of a growing number of centers, including those at Johns Hopkins University and the University of Toronto, where technologists and clinicians have teamed up to develop ambient intelligence technologies to help health care providers manage patient volumes, roughly 24 million Americans required an overnight hospital stay in 2018.

Haque, who compiled the 170 scientific papers cited in the Nature article, the availability of infrared sensors that are inexpensive enough to build into high-risk care-giving environments, and the rise of machine learning systems as a way to use sensor input to train specialized AI applications in health care.

The infrared technologies are of two types. The first is active infrared, such as the invisible light beams used by TV remote controls. Nonetheless as an alternative of simply beaming invisible light in one direction, like a TV remote, new active infrared systems use AI to compute the time it takes the invisible rays to bounce back to the source, like a light-based form of radar that maps the 3D outlines of a person or object.

These alert systems are being confirmed to see if they can reduce the number of ICU patients who get nosocomial infections due to failure of other people in the hospital to fully observe to infection prevention protocols.

The second type of infrared technology are passive detectors, that allow night vision goggles to generate thermal images from the infrared rays generated by body heat. In a hospital setting, a thermal sensor above an ICU bed would allow the governing AI to sense twitching beneath the sheets, and alert clinical team members to forthcoming health crises without continuously going from room to room.

Constant monitoring by ambient intelligence systems in a home environment could also be used to detect clues of serious illness or potential accidents, and alert caregivers to make timely interventions. . Researchers are still developing activity recognition algorithms that can examine through infrared sensing data to detect variations in habitual behaviors, and benefit caregivers get a more holistic view of patient health.

SOURCE

https://engineering.stanford.edu/magazine/article/ai-controlled-sensors-could-save-lives-smart-hospitals-and-homes

 

Read Full Post »


Tweets & Retweets by @pharma_BI and @AVIVA1950 at #BioIT20, 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 in Boston

 

Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN

 

Amazing conference ended at 2PM on October 8, 2020

e-Proceedings 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 Boston

Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/03/26/19th-annual-bio-it-world-2020-conference-october-6-8-2020-in-boston/

Review Tweets and Retweets

and 2 others liked your Tweet

#BioIT20 Plenary Keynote: cutting innovative approach to #Science #Game On: How #AI, #CitizenScience #HumanComputation are facilitating the next leap forward in #Genomics and in #Biology may be in #PrecisionMedicine in the Future @pharma_BI @AVIVA1950 pic.twitter.com/L52qktkeYc

Retweeted your Tweet
#BioIT20 Plenary Keynote: cutting innovative approach to #Science #Game On: How #AI, #CitizenScience #HumanComputation are facilitating the next leap forward in #Genomics and in #Biology may be in #PrecisionMedicine in the Future @pharma_BI @AVIVA1950 pic.twitter.com/L52qktkeYc

and

liked your Tweet

#BioIT20 Plenary Keynote: cutting innovative approach to #Science #Game On: How #AI, #CitizenScience #HumanComputation are facilitating the next leap forward in #Genomics and in #Biology may be in #PrecisionMedicine in the Future @pharma_BI @AVIVA1950 pic.twitter.com/L52qktkeYc

NIH Office of Data Science Strategy
@NIHDataScience

We’ve made progress with #FAIRData, but we still have a ways to go and our future is bright. #BioIT20 #NIHData

Image

3

Aviva Lev-Ari
@AVIVA1950

#BioIT20

Driving Scientific Discovery with Data Digitization great ideas shared by moderator Timothy Gardner

#CEO Inspiration from History Total Quality Implementation is key for BioScience Data #AI won’t solve the problem #Data #Quality will

Image

Rob Lalonde
@HPC_Cloud_Rob

My #BioIT20 talk, “#Bioinformatics in the #Cloud Age,” is tomorrow at 3:30pm. I discuss cloud migration trends in life sciences and #HPC. Join us! A panel with

and

follows the talk.

1
16

Jean Marois
@JeanMarois

My team is participating in Bio-IT World Virtual 2020, October 6-8. Join me! Use discount code 20NUA to save 20%! invt.io/1tdbae9s8lp

#BioIT20

I’m going to Bio-IT World 2020, Oct 6-8, from home! Its a virtual event. Join me!
My team is participating in Bio-IT World Virtual 2020, October 6-8. Join me! Use discount code 20NUA to save 20%! @bioitworld #BioIT20
invt.io
2

NIH Office of Data Science Strategy
@NIHDataScience

One of the challenges we face today: we need an algorithm that can search across the 36+ PB of Sequence Read Archive (SRA) data now in the cloud. Imagine what we could do! #BioIT20 #NIHdata #SRAdata

Image

2

NCBI Staff
@NCBI

NCBI’s virtual #BioIT20 booth will open in 15 minutes. There, you can watch videos, grab some flyers and even speak with an expert! bio-itworld.pathable.co/organizations/ The booth will close at 4:15 PM, but we’ll be back tomorrow, Oct 7 and Thursday, Oct 8 at 9AM.
Bio-IT World
Welcome to Bio-IT World Virtual
bio-itworld.pathable.co
1
6
Show this thread

PERCAYAI
@percayai

Happening soon at #BioIT20: Join our faculty inventor Professor Rich Head’s invited talk “CompBio: An Augmented Intelligence System for Comprehensive Interpretation of Biological Data.”
4

Wendy Anne Warr
@WendyAnneWarr

This was a good discussion
Quote Tweet
Cambridge Innovation
@CIInstitute
·
RT percayai: We’ve put together what’s sure to be a thought-provoking discussion group for #BioIT20 “Why Current Approaches Using #AI in #…
1
2

Cambridge Innovation
@CIInstitute

RT VishakhaSharma_: Excited to speak and moderate a panel on Emerging #AI technologies bioitworld #BioIT20
1

Titian Software
@TitianSoftware

Meet Titian at #BioIT20 on 6-8th October and discover the latest research, science and solutions for exploring the world of precision medicine and the technologies that are powering it: bit.ly/2GjCj4B

Image

1

PERCAYAI
@percayai

Thanks for joining us, Wendy! You’ve done a great job summing up key points from the discussion. #BioIT20
1

Aviva Lev-Ari
@AVIVA1950

#NIHhealthInitiative #BioItWorld20

Out standing Plenary Keynote on #DataScience

CONNECTED DATA ECOSYSTEM FAIR Foundable, Accessible, Interoperable, reusable

Image

2

Read Full Post »


2020 AAAI US$1M Annual Award for Societal Impact of Artificial Intelligence goes to MIT’s CSAIL Professor, Regina Barzilay

 

Barzilay’s work in AI, which ranges from tools for early cancer detection to platforms to identify new antibiotics, is increasingly garnering recognition: On Wednesday, the Association for the Advancement of Artificial Intelligence named Barzilay as the inaugural recipient of a new annual award honoring an individual developing or promoting AI for the good of society. The award comes with a $1 million prize sponsored by the Chinese education technology company Squirrel AI Learning.

Barzilay’s treatment was successful, and she believes her clinical team at MGH did the best they could in providing her with standard care. At the same time, she said, “it was extremely not satisfying to see how the simplest things that the technology can address were not addressed” — including a delayed diagnosis, an inability to collect data, and statistical flaws in studies used to make treatment decisions.

AAAI and Squirrel AI Learning Announce the Establishment of US$1M Annual Award for Societal Impact of Artificial Intelligence

May 28, 2019
Beijing, China

The Association for the Advancement of Artificial Intelligence (AAAI) and Squirrel AI Learning announced the establishment of a new $1M annual award for societal benefits of AI. The award will be sponsored by Squirrel AI Learning as part of its mission to promote the use of artificial intelligence with lasting positive effects for society.

The new Squirrel AI Award for Artificial Intelligence to Benefit Humanity was announced jointly by Derek Haoyang Li, Founder and Chairman of Squirrel AI Learning, and Yolanda Gil, President of AAAI, at the 2019 conference for AI for adaptive Education (AIAED) in Beijing.

https://aaai.org/Pressroom/Releases/release-19-0528.php

SOURCE

https://www.statnews.com/2020/09/23/regina-barzilay-mit-artificial-intelligence-award/?utm_source=STAT+Newsletters&utm_campaign=0bceb5f630-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-0bceb5f630-150237109

Read Full Post »


AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD

 

Inclusion of this Scientific Report was inspired by 

2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020

https://pharmaceuticalintelligence.com/2020/02/21/2020-state-of-possible-conference-massbios-annual-meeting-march-25-26-2020-sonesta-hotel-cambridge-ma/

 

10:15 AM – 10:45 AM EDT
(30 Min)

Science Breakout: AI and Drug Discovery: Marrying Data Science with Core Biology

Colin HillChief Executive Officer, President, Chairman, and Co-Founder GNS Healthcare Moderator 

Juan Alvarez AVP, Computational and Structural Chemistry Merck & Co., Inc. Panelist

  • Drug Target identification
  • Drug Discovery – ML since 1980s
  • Identify moleduces
  • syntesis prediction
  • physico space
  • evolving proteins
  • analysing data

Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group Panelist

  • technology enable company clinical data analysis of data clical trials 
  • ML prior knowledge
  • network biology 
  • drive inside 
  • MOA prioritize indications 

Rachel Hodos Senior AI Scientist Benevolent AI Panelist

Nora Khaldi Founder and CSO Nuritas Panelist

 

Read Full Post »


Systems Biology analysis of Transcription Networks, Artificial Intelligence, and High-End Computing Coming to Fruition in Personalized Oncology

Curator: Stephen J. Williams, Ph.D.

In the June 2020 issue of the journal Science, writer Roxanne Khamsi has an interesting article “Computing Cancer’s Weak Spots; An algorithm to unmask tumors’ molecular linchpins is tested in patients”[1], describing some early successes in the incorporation of cancer genome sequencing in conjunction with artificial intelligence algorithms toward a personalized clinical treatment decision for various tumor types.  In 2016, oncologists Amy Tiersten collaborated with systems biologist Andrea Califano and cell biologist Jose Silva at Mount Sinai Hospital to develop a systems biology approach to determine that the drug ruxolitinib, a STAT3 inhibitor, would be effective for one of her patient’s aggressively recurring, Herceptin-resistant breast tumor.  Dr. Califano, instead of defining networks of driver mutations, focused on identifying a few transcription factors that act as ‘linchpins’ or master controllers of transcriptional networks withing tumor cells, and in doing so hoping to, in essence, ‘bottleneck’ the transcriptional machinery of potential oncogenic products. As Dr. Castilano states

“targeting those master regulators and you will stop cancer in its tracks, no matter what mutation initially caused it.”

It is important to note that this approach also relies on the ability to sequence tumors  by RNA-seq to determine the underlying mutations which alter which master regulators are pertinent in any one tumor.  And given the wide tumor heterogeneity in tumor samples, this sequencing effort may have to involve multiple biopsies (as discussed in earlier posts on tumor heterogeneity in renal cancer).

As stated in the article, Califano co-founded a company called Darwin-Health in 2015 to guide doctors by identifying the key transcription factors in a patient’s tumor and suggesting personalized therapeutics to those identified molecular targets (OncoTarget™).  He had collaborated with the Jackson Laboratory and most recently Columbia University to conduct a $15 million 3000 patient clinical trial.  This was a bit of a stretch from his initial training as a physicist and, in 1986, IBM hired him for some artificial intelligence projects.  He then landed in 2003 at Columbia and has been working on identifying these transcriptional nodes that govern cancer survival and tumorigenicity.  Dr. Califano had figured that the number of genetic mutations which potentially could be drivers were too vast:

A 2018 study which analyzed more than 9000 tumor samples reported over 1.5 million mutations[2]

and impossible to develop therapeutics against.  He reasoned that you would just have to identify the common connections between these pathways or transcriptional nodes and termed them master regulators.

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

Chen H, Li C, Peng X, et al. Cell. 2018;173(2):386-399.e12.

Abstract

The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer development has increasingly been appreciated. Here, we present the detection and characterization of a large number of expressed enhancers in a genome-wide analysis of 8928 tumor samples across 33 cancer types using TCGA RNA-seq data. Compared with matched normal tissues, global enhancer activation was observed in most cancers. Across cancer types, global enhancer activity was positively associated with aneuploidy, but not mutation load, suggesting a hypothesis centered on “chromatin-state” to explain their interplay. Integrating eQTL, mRNA co-expression, and Hi-C data analysis, we developed a computational method to infer causal enhancer-gene interactions, revealing enhancers of clinically actionable genes. Having identified an enhancer ∼140 kb downstream of PD-L1, a major immunotherapy target, we validated it experimentally. This study provides a systematic view of enhancer activity in diverse tumor contexts and suggests the clinical implications of enhancers.

 

A diagram of how concentrating on these transcriptional linchpins or nodes may be more therapeutically advantageous as only one pharmacologic agent is needed versus multiple agents to inhibit the various upstream pathways:

 

 

From: Khamsi R: Computing cancer’s weak spots. Science 2020, 368(6496):1174-1177.

 

VIPER Algorithm (Virtual Inference of Protein activity by Enriched Regulon Analysis)

The algorithm that Califano and DarwinHealth developed is a systems biology approach using a tumor’s RNASeq data to determine controlling nodes of transcription.  They have recently used the VIPER algorithm to look at RNA-Seq data from more than 10,000 tumor samples from TCGA and identified 407 transcription factor genes that acted as these linchpins across all tumor types.  Only 20 to 25 of  them were implicated in just one tumor type so these potential nodes are common in many forms of cancer.

Other institutions like the Cold Spring Harbor Laboratories have been using VIPER in their patient tumor analysis.  Linchpins for other tumor types have been found.  For instance, VIPER identified transcription factors IKZF1 and IKF3 as linchpins in multiple myeloma.  But currently approved therapeutics are hard to come by for targets with are transcription factors, as most pharma has concentrated on inhibiting an easier target like kinases and their associated activity.  In general, developing transcription factor inhibitors in more difficult an undertaking for multiple reasons.

Network-based inference of protein activity helps functionalize the genetic landscape of cancer. Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, Califano A:. Nature genetics 2016, 48(8):838-847 [3]

Abstract

Identifying the multiple dysregulated oncoproteins that contribute to tumorigenesis in a given patient is crucial for developing personalized treatment plans. However, accurate inference of aberrant protein activity in biological samples is still challenging as genetic alterations are only partially predictive and direct measurements of protein activity are generally not feasible. To address this problem we introduce and experimentally validate a new algorithm, VIPER (Virtual Inference of Protein-activity by Enriched Regulon analysis), for the accurate assessment of protein activity from gene expression data. We use VIPER to evaluate the functional relevance of genetic alterations in regulatory proteins across all TCGA samples. In addition to accurately inferring aberrant protein activity induced by established mutations, we also identify a significant fraction of tumors with aberrant activity of druggable oncoproteins—despite a lack of mutations, and vice-versa. In vitro assays confirmed that VIPER-inferred protein activity outperforms mutational analysis in predicting sensitivity to targeted inhibitors.

 

 

 

 

Figure 1 

Schematic overview of the VIPER algorithm From: Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, Califano A: Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nature genetics 2016, 48(8):838-847.

(a) Molecular layers profiled by different technologies. Transcriptomics measures steady-state mRNA levels; Proteomics quantifies protein levels, including some defined post-translational isoforms; VIPER infers protein activity based on the protein’s regulon, reflecting the abundance of the active protein isoform, including post-translational modifications, proper subcellular localization and interaction with co-factors. (b) Representation of VIPER workflow. A regulatory model is generated from ARACNe-inferred context-specific interactome and Mode of Regulation computed from the correlation between regulator and target genes. Single-sample gene expression signatures are computed from genome-wide expression data, and transformed into regulatory protein activity profiles by the aREA algorithm. (c) Three possible scenarios for the aREA analysis, including increased, decreased or no change in protein activity. The gene expression signature and its absolute value (|GES|) are indicated by color scale bars, induced and repressed target genes according to the regulatory model are indicated by blue and red vertical lines. (d) Pleiotropy Correction is performed by evaluating whether the enrichment of a given regulon (R4) is driven by genes co-regulated by a second regulator (R4∩R1). (e) Benchmark results for VIPER analysis based on multiple-samples gene expression signatures (msVIPER) and single-sample gene expression signatures (VIPER). Boxplots show the accuracy (relative rank for the silenced protein), and the specificity (fraction of proteins inferred as differentially active at p < 0.05) for the 6 benchmark experiments (see Table 2). Different colors indicate different implementations of the aREA algorithm, including 2-tail (2T) and 3-tail (3T), Interaction Confidence (IC) and Pleiotropy Correction (PC).

 Other articles from Andrea Califano on VIPER algorithm in cancer include:

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.

Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H.Sci Transl Med. 2019 Apr 17;11(488):eaav0936. doi: 10.1126/scitranslmed.aav0936.PMID: 30996079

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA.Cell Rep. 2017 Aug 15;20(7):1623-1640. doi: 10.1016/j.celrep.2017.07.052.PMID: 28813674

Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM.Genes Dev. 2015 Aug 1;29(15):1631-48. doi: 10.1101/gad.262642.115. Epub 2015 Jul 30.PMID: 26227964

Master regulators used as breast cancer metastasis classifier.

Lim WK, Lyashenko E, Califano A.Pac Symp Biocomput. 2009:504-15.PMID: 19209726 Free

 

Additional References

 

  1. Khamsi R: Computing cancer’s weak spots. Science 2020, 368(6496):1174-1177.
  2. Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Liang H: A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell 2018, 173(2):386-399 e312.
  3. Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, Califano A: Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nature genetics 2016, 48(8):838-847.

 

Other articles of Note on this Open Access Online Journal Include:

Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

 

Read Full Post »


Live Notes, Real Time Conference Coverage AACR 2020: Tuesday June 23, 2020 3:00 PM-5:30 PM Educational Sessions

Reporter: Stephen J. Williams, PhD

Follow Live in Real Time using

#AACR20

@pharma_BI

@AACR

Register for FREE at https://www.aacr.org/

uesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Tumor Biology, Bioinformatics and Systems Biology

The Clinical Proteomic Tumor Analysis Consortium: Resources and Data Dissemination

This session will provide information regarding methodologic and computational aspects of proteogenomic analysis of tumor samples, particularly in the context of clinical trials. Availability of comprehensive proteomic and matching genomic data for tumor samples characterized by the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) program will be described, including data access procedures and informatic tools under development. Recent advances on mass spectrometry-based targeted assays for inclusion in clinical trials will also be discussed.

Amanda G Paulovich, Shankha Satpathy, Meenakshi Anurag, Bing Zhang, Steven A Carr

Methods and tools for comprehensive proteogenomic characterization of bulk tumor to needle core biopsies

Shankha Satpathy
  • TCGA has 11,000 cancers with >20,000 somatic alterations but only 128 proteins as proteomics was still young field
  • CPTAC is NCI proteomic effort
  • Chemical labeling approach now method of choice for quantitative proteomics
  • Looked at ovarian and breast cancers: to measure PTM like phosphorylated the sample preparation is critical

 

Data access and informatics tools for proteogenomics analysis

Bing Zhang
  • Raw and processed data (raw MS data) with linked clinical data can be extracted in CPTAC
  • Python scripts are available for bioinformatic programming

 

Pathways to clinical translation of mass spectrometry-based assays

Meenakshi Anurag

·         Using kinase inhibitor pulldown (KIP) assay to identify unique kinome profiles

·         Found single strand break repair defects in endometrial luminal cases, especially with immune checkpoint prognostic tumors

·         Paper: JNCI 2019 analyzed 20,000 genes correlated with ET resistant in luminal B cases (selected for a list of 30 genes)

·         Validated in METABRIC dataset

·         KIP assay uses magnetic beads to pull out kinases to determine druggable kinases

·         Looked in xenografts and was able to pull out differential kinomes

·         Matched with PDX data so good clinical correlation

·         Were able to detect ESR1 fusion correlated with ER+ tumors

Tuesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Survivorship

Artificial Intelligence and Machine Learning from Research to the Cancer Clinic

The adoption of omic technologies in the cancer clinic is giving rise to an increasing number of large-scale high-dimensional datasets recording multiple aspects of the disease. This creates the need for frameworks for translatable discovery and learning from such data. Like artificial intelligence (AI) and machine learning (ML) for the cancer lab, methods for the clinic need to (i) compare and integrate different data types; (ii) scale with data sizes; (iii) prove interpretable in terms of the known biology and batch effects underlying the data; and (iv) predict previously unknown experimentally verifiable mechanisms. Methods for the clinic, beyond the lab, also need to (v) produce accurate actionable recommendations; (vi) prove relevant to patient populations based upon small cohorts; and (vii) be validated in clinical trials. In this educational session we will present recent studies that demonstrate AI and ML translated to the cancer clinic, from prognosis and diagnosis to therapy.
NOTE: Dr. Fish’s talk is not eligible for CME credit to permit the free flow of information of the commercial interest employee participating.

Ron C. Anafi, Rick L. Stevens, Orly Alter, Guy Fish

Overview of AI approaches in cancer research and patient care

Rick L. Stevens
  • Deep learning is less likely to saturate as data increases
  • Deep learning attempts to learn multiple layers of information
  • The ultimate goal is prediction but this will be the greatest challenge for ML
  • ML models can integrate data validation and cross database validation
  • What limits the performance of cross validation is the internal noise of data (reproducibility)
  • Learning curves: not the more data but more reproducible data is important
  • Neural networks can outperform classical methods
  • Important to measure validation accuracy in training set. Class weighting can assist in development of data set for training set especially for unbalanced data sets

Discovering genome-scale predictors of survival and response to treatment with multi-tensor decompositions

Orly Alter
  • Finding patterns using SVD component analysis. Gene and SVD patterns match 1:1
  • Comparative spectral decompositions can be used for global datasets
  • Validation of CNV data using this strategy
  • Found Ras, Shh and Notch pathways with altered CNV in glioblastoma which correlated with prognosis
  • These predictors was significantly better than independent prognostic indicator like age of diagnosis

 

Identifying targets for cancer chronotherapy with unsupervised machine learning

Ron C. Anafi
  • Many clinicians have noticed that some patients do better when chemo is given at certain times of the day and felt there may be a circadian rhythm or chronotherapeutic effect with respect to side effects or with outcomes
  • ML used to determine if there is indeed this chronotherapy effect or can we use unstructured data to determine molecular rhythms?
  • Found a circadian transcription in human lung
  • Most dataset in cancer from one clinical trial so there might need to be more trials conducted to take into consideration circadian rhythms

Stratifying patients by live-cell biomarkers with random-forest decision trees

Stratifying patients by live-cell biomarkers with random-forest decision trees

Guy Fish CEO Cellanyx Diagnostics

 

Tuesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Tumor Biology, Molecular and Cellular Biology/Genetics, Bioinformatics and Systems Biology, Prevention Research

The Wound Healing that Never Heals: The Tumor Microenvironment (TME) in Cancer Progression

This educational session focuses on the chronic wound healing, fibrosis, and cancer “triad.” It emphasizes the similarities and differences seen in these conditions and attempts to clarify why sustained fibrosis commonly supports tumorigenesis. Importance will be placed on cancer-associated fibroblasts (CAFs), vascularity, extracellular matrix (ECM), and chronic conditions like aging. Dr. Dvorak will provide an historical insight into the triad field focusing on the importance of vascular permeability. Dr. Stewart will explain how chronic inflammatory conditions, such as the aging tumor microenvironment (TME), drive cancer progression. The session will close with a review by Dr. Cukierman of the roles that CAFs and self-produced ECMs play in enabling the signaling reciprocity observed between fibrosis and cancer in solid epithelial cancers, such as pancreatic ductal adenocarcinoma.

Harold F Dvorak, Sheila A Stewart, Edna Cukierman

 

The importance of vascular permeability in tumor stroma generation and wound healing

Harold F Dvorak

Aging in the driver’s seat: Tumor progression and beyond

Sheila A Stewart

Why won’t CAFs stay normal?

Edna Cukierman

 

Tuesday, June 23

3:00 PM – 5:00 PM EDT

 

 

 

 

 

 

 

Other Articles on this Open Access  Online Journal on Cancer Conferences and Conference Coverage in Real Time Include

Press Coverage
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on NCI Activities: COVID-19 and Cancer Research 5:20 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Evaluating Cancer Genomics from Normal Tissues Through Metastatic Disease 3:50 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Novel Targets and Therapies 2:35 PM

Read Full Post »

Live Notes, Real Time Conference Coverage AACR 2020 #AACR20: Tuesday June 23, 2020 Noon-2:45 Educational Sessions


Live Notes, Real Time Conference Coverage AACR 2020: Tuesday June 23, 2020 Noon-2:45 Educational Sessions

Reporter: Stephen J. Williams, PhD

Follow Live in Real Time using

#AACR20

@pharma_BI

@AACR

Register for FREE at https://www.aacr.org/

 

Presidential Address

Elaine R Mardis, William N Hait

DETAILS

Welcome and introduction

William N Hait

 

Improving diagnostic yield in pediatric cancer precision medicine

Elaine R Mardis
  • Advent of genomics have revolutionized how we diagnose and treat lung cancer
  • We are currently needing to understand the driver mutations and variants where we can personalize therapy
  • PD-L1 and other checkpoint therapy have not really been used in pediatric cancers even though CAR-T have been successful
  • The incidence rates and mortality rates of pediatric cancers are rising
  • Large scale study of over 700 pediatric cancers show cancers driven by epigenetic drivers or fusion proteins. Need for transcriptomics.  Also study demonstrated that we have underestimated germ line mutations and hereditary factors.
  • They put together a database to nominate patients on their IGM Cancer protocol. Involves genetic counseling and obtaining germ line samples to determine hereditary factors.  RNA and protein are evaluated as well as exome sequencing. RNASeq and Archer Dx test to identify driver fusions
  • PECAN curated database from St. Jude used to determine driver mutations. They use multiple databases and overlap within these databases and knowledge base to determine or weed out false positives
  • They have used these studies to understand the immune infiltrate into recurrent cancers (CytoCure)
  • They found 40 germline cancer predisposition genes, 47 driver somatic fusion proteins, 81 potential actionable targets, 106 CNV, 196 meaningful somatic driver mutations

 

 

Tuesday, June 23

12:00 PM – 12:30 PM EDT

Awards and Lectures

NCI Director’s Address

Norman E Sharpless, Elaine R Mardis

DETAILS

Introduction: Elaine Mardis

 

NCI Director Address: Norman E Sharpless
  • They are functioning well at NCI with respect to grant reviews, research, and general functions in spite of the COVID pandemic and the massive demonstrations on also focusing on the disparities which occur in cancer research field and cancer care
  • There are ongoing efforts at NCI to make a positive difference in racial injustice, diversity in the cancer workforce, and for patients as well
  • Need a diverse workforce across the cancer research and care spectrum
  • Data show that areas where the clinicians are successful in putting African Americans on clinical trials are areas (geographic and site specific) where health disparities are narrowing
  • Grants through NCI new SeroNet for COVID-19 serologic testing funded by two RFAs through NIAD (RFA-CA-30-038 and RFA-CA-20-039) and will close on July 22, 2020

 

Tuesday, June 23

12:45 PM – 1:46 PM EDT

Virtual Educational Session

Immunology, Tumor Biology, Experimental and Molecular Therapeutics, Molecular and Cellular Biology/Genetics

Tumor Immunology and Immunotherapy for Nonimmunologists: Innovation and Discovery in Immune-Oncology

This educational session will update cancer researchers and clinicians about the latest developments in the detailed understanding of the types and roles of immune cells in tumors. It will summarize current knowledge about the types of T cells, natural killer cells, B cells, and myeloid cells in tumors and discuss current knowledge about the roles these cells play in the antitumor immune response. The session will feature some of the most promising up-and-coming cancer immunologists who will inform about their latest strategies to harness the immune system to promote more effective therapies.

Judith A Varner, Yuliya Pylayeva-Gupta

 

Introduction

Judith A Varner
New techniques reveal critical roles of myeloid cells in tumor development and progression
  • Different type of cells are becoming targets for immune checkpoint like myeloid cells
  • In T cell excluded or desert tumors T cells are held at periphery so myeloid cells can infiltrate though so macrophages might be effective in these immune t cell naïve tumors, macrophages are most abundant types of immune cells in tumors
  • CXCLs are potential targets
  • PI3K delta inhibitors,
  • Reduce the infiltrate of myeloid tumor suppressor cells like macrophages
  • When should we give myeloid or T cell therapy is the issue
Judith A Varner
Novel strategies to harness T-cell biology for cancer therapy
Positive and negative roles of B cells in cancer
Yuliya Pylayeva-Gupta
New approaches in cancer immunotherapy: Programming bacteria to induce systemic antitumor immunity

 

 

Tuesday, June 23

12:45 PM – 1:46 PM EDT

Virtual Educational Session

Cancer Chemistry

Chemistry to the Clinic: Part 2: Irreversible Inhibitors as Potential Anticancer Agents

There are numerous examples of highly successful covalent drugs such as aspirin and penicillin that have been in use for a long period of time. Despite historical success, there was a period of reluctance among many to purse covalent drugs based on concerns about toxicity. With advances in understanding features of a well-designed covalent drug, new techniques to discover and characterize covalent inhibitors, and clinical success of new covalent cancer drugs in recent years, there is renewed interest in covalent compounds. This session will provide a broad look at covalent probe compounds and drug development, including a historical perspective, examination of warheads and electrophilic amino acids, the role of chemoproteomics, and case studies.

Benjamin F Cravatt, Richard A. Ward, Sara J Buhrlage

 

Discovering and optimizing covalent small-molecule ligands by chemical proteomics

Benjamin F Cravatt
  • Multiple approaches are being investigated to find new covalent inhibitors such as: 1) cysteine reactivity mapping, 2) mapping cysteine ligandability, 3) and functional screening in phenotypic assays for electrophilic compounds
  • Using fluorescent activity probes in proteomic screens; have broad useability in the proteome but can be specific
  • They screened quiescent versus stimulated T cells to determine reactive cysteines in a phenotypic screen and analyzed by MS proteomics (cysteine reactivity profiling); can quantitate 15000 to 20,000 reactive cysteines
  • Isocitrate dehydrogenase 1 and adapter protein LCP-1 are two examples of changes in reactive cysteines they have seen using this method
  • They use scout molecules to target ligands or proteins with reactive cysteines
  • For phenotypic screens they first use a cytotoxic assay to screen out toxic compounds which just kill cells without causing T cell activation (like IL10 secretion)
  • INTERESTINGLY coupling these MS reactive cysteine screens with phenotypic screens you can find NONCANONICAL mechanisms of many of these target proteins (many of the compounds found targets which were not predicted or known)

Electrophilic warheads and nucleophilic amino acids: A chemical and computational perspective on covalent modifier

The covalent targeting of cysteine residues in drug discovery and its application to the discovery of Osimertinib

Richard A. Ward
  • Cysteine activation: thiolate form of cysteine is a strong nucleophile
  • Thiolate form preferred in polar environment
  • Activation can be assisted by neighboring residues; pKA will have an effect on deprotonation
  • pKas of cysteine vary in EGFR
  • cysteine that are too reactive give toxicity while not reactive enough are ineffective

 

Accelerating drug discovery with lysine-targeted covalent probes

 

Tuesday, June 23

12:45 PM – 2:15 PM EDT

Virtual Educational Session

Molecular and Cellular Biology/Genetics

Virtual Educational Session

Tumor Biology, Immunology

Metabolism and Tumor Microenvironment

This Educational Session aims to guide discussion on the heterogeneous cells and metabolism in the tumor microenvironment. It is now clear that the diversity of cells in tumors each require distinct metabolic programs to survive and proliferate. Tumors, however, are genetically programmed for high rates of metabolism and can present a metabolically hostile environment in which nutrient competition and hypoxia can limit antitumor immunity.

Jeffrey C Rathmell, Lydia Lynch, Mara H Sherman, Greg M Delgoffe

 

T-cell metabolism and metabolic reprogramming antitumor immunity

Jeffrey C Rathmell

Introduction

Jeffrey C Rathmell

Metabolic functions of cancer-associated fibroblasts

Mara H Sherman

Tumor microenvironment metabolism and its effects on antitumor immunity and immunotherapeutic response

Greg M Delgoffe
  • Multiple metabolites, reactive oxygen species within the tumor microenvironment; is there heterogeneity within the TME metabolome which can predict their ability to be immunosensitive
  • Took melanoma cells and looked at metabolism using Seahorse (glycolysis): and there was vast heterogeneity in melanoma tumor cells; some just do oxphos and no glycolytic metabolism (inverse Warburg)
  • As they profiled whole tumors they could separate out the metabolism of each cell type within the tumor and could look at T cells versus stromal CAFs or tumor cells and characterized cells as indolent or metabolic
  • T cells from hyerglycolytic tumors were fine but from high glycolysis the T cells were more indolent
  • When knock down glucose transporter the cells become more glycolytic
  • If patient had high oxidative metabolism had low PDL1 sensitivity
  • Showed this result in head and neck cancer as well
  • Metformin a complex 1 inhibitor which is not as toxic as most mito oxphos inhibitors the T cells have less hypoxia and can remodel the TME and stimulate the immune response
  • Metformin now in clinical trials
  • T cells though seem metabolically restricted; T cells that infiltrate tumors are low mitochondrial phosph cells
  • T cells from tumors have defective mitochondria or little respiratory capacity
  • They have some preliminary findings that metabolic inhibitors may help with CAR-T therapy

Obesity, lipids and suppression of anti-tumor immunity

Lydia Lynch
  • Hypothesis: obesity causes issues with anti tumor immunity
  • Less NK cells in obese people; also produce less IFN gamma
  • RNASeq on NOD mice; granzymes and perforins at top of list of obese downregulated
  • Upregulated genes that were upregulated involved in lipid metabolism
  • All were PPAR target genes
  • NK cells from obese patients takes up palmitate and this reduces their glycolysis but OXPHOS also reduced; they think increased FFA basically overloads mitochondria
  • PPAR alpha gamma activation mimics obesity

 

 

Tuesday, June 23

12:45 PM – 2:45 PM EDT

Virtual Educational Session

Clinical Research Excluding Trials

The Evolving Role of the Pathologist in Cancer Research

Long recognized for their role in cancer diagnosis and prognostication, pathologists are beginning to leverage a variety of digital imaging technologies and computational tools to improve both clinical practice and cancer research. Remarkably, the emergence of artificial intelligence (AI) and machine learning algorithms for analyzing pathology specimens is poised to not only augment the resolution and accuracy of clinical diagnosis, but also fundamentally transform the role of the pathologist in cancer science and precision oncology. This session will discuss what pathologists are currently able to achieve with these new technologies, present their challenges and barriers, and overview their future possibilities in cancer diagnosis and research. The session will also include discussions of what is practical and doable in the clinic for diagnostic and clinical oncology in comparison to technologies and approaches primarily utilized to accelerate cancer research.

 

Jorge S Reis-Filho, Thomas J Fuchs, David L Rimm, Jayanta Debnath

DETAILS

Tuesday, June 23

12:45 PM – 2:45 PM EDT

 

High-dimensional imaging technologies in cancer research

David L Rimm

  • Using old methods and new methods; so cell counting you use to find the cells then phenotype; with quantification like with Aqua use densitometry of positive signal to determine a threshold to determine presence of a cell for counting
  • Hiplex versus multiplex imaging where you have ten channels to measure by cycling of flour on antibody (can get up to 20plex)
  • Hiplex can be coupled with Mass spectrometry (Imaging Mass spectrometry, based on heavy metal tags on mAbs)
  • However it will still take a trained pathologist to define regions of interest or field of desired view

 

Introduction

Jayanta Debnath

Challenges and barriers of implementing AI tools for cancer diagnostics

Jorge S Reis-Filho

Implementing robust digital pathology workflows into clinical practice and cancer research

Jayanta Debnath

Invited Speaker

Thomas J Fuchs
  • Founder of spinout of Memorial Sloan Kettering
  • Separates AI from computational algothimic
  • Dealing with not just machines but integrating human intelligence
  • Making decision for the patients must involve human decision making as well
  • How do we get experts to do these decisions faster
  • AI in pathology: what is difficult? =è sandbox scenarios where machines are great,; curated datasets; human decision support systems or maps; or try to predict nature
  • 1) learn rules made by humans; human to human scenario 2)constrained nature 3)unconstrained nature like images and or behavior 4) predict nature response to nature response to itself
  • In sandbox scenario the rules are set in stone and machines are great like chess playing
  • In second scenario can train computer to predict what a human would predict
  • So third scenario is like driving cars
  • System on constrained nature or constrained dataset will take a long time for commuter to get to decision
  • Fourth category is long term data collection project
  • He is finding it is still finding it is still is difficult to predict nature so going from clinical finding to prognosis still does not have good predictability with AI alone; need for human involvement
  • End to end partnering (EPL) is a new way where humans can get more involved with the algorithm and assist with the problem of constrained data
  • An example of a workflow for pathology would be as follows from Campanella et al 2019 Nature Medicine: obtain digital images (they digitized a million slides), train a massive data set with highthroughput computing (needed a lot of time and big software developing effort), and then train it using input be the best expert pathologists (nature to human and unconstrained because no data curation done)
  • Led to first clinically grade machine learning system (Camelyon16 was the challenge for detecting metastatic cells in lymph tissue; tested on 12,000 patients from 45 countries)
  • The first big hurdle was moving from manually annotated slides (which was a big bottleneck) to automatically extracted data from path reports).
  • Now problem is in prediction: How can we bridge the gap from predicting humans to predicting nature?
  • With an AI system pathologist drastically improved the ability to detect very small lesions

 

Virtual Educational Session

Epidemiology

Cancer Increases in Younger Populations: Where Are They Coming from?

Incidence rates of several cancers (e.g., colorectal, pancreatic, and breast cancers) are rising in younger populations, which contrasts with either declining or more slowly rising incidence in older populations. Early-onset cancers are also more aggressive and have different tumor characteristics than those in older populations. Evidence on risk factors and contributors to early-onset cancers is emerging. In this Educational Session, the trends and burden, potential causes, risk factors, and tumor characteristics of early-onset cancers will be covered. Presenters will focus on colorectal and breast cancer, which are among the most common causes of cancer deaths in younger people. Potential mechanisms of early-onset cancers and racial/ethnic differences will also be discussed.

Stacey A. Fedewa, Xavier Llor, Pepper Jo Schedin, Yin Cao

Cancers that are and are not increasing in younger populations

Stacey A. Fedewa

 

  • Early onset cancers, pediatric cancers and colon cancers are increasing in younger adults
  • Younger people are more likely to be uninsured and these are there most productive years so it is a horrible life event for a young adult to be diagnosed with cancer. They will have more financial hardship and most (70%) of the young adults with cancer have had financial difficulties.  It is very hard for women as they are on their childbearing years so additional stress
  • Types of early onset cancer varies by age as well as geographic locations. For example in 20s thyroid cancer is more common but in 30s it is breast cancer.  Colorectal and testicular most common in US.
  • SCC is decreasing by adenocarcinoma of the cervix is increasing in women’s 40s, potentially due to changing sexual behaviors
  • Breast cancer is increasing in younger women: maybe etiologic distinct like triple negative and larger racial disparities in younger African American women
  • Increased obesity among younger people is becoming a factor in this increasing incidence of early onset cancers

 

 

Other Articles on this Open Access  Online Journal on Cancer Conferences and Conference Coverage in Real Time Include

Press Coverage

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on NCI Activities: COVID-19 and Cancer Research 5:20 PM

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Evaluating Cancer Genomics from Normal Tissues Through Metastatic Disease 3:50 PM

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Novel Targets and Therapies 2:35 PM

 

Read Full Post »


Powerful AI Tools Being Developed for the COVID-19 Fight

Curator: Stephen J. Williams, Ph.D.

 

Source: https://www.ibm.com/blogs/research/2020/04/ai-powered-technologies-accelerate-discovery-covid-19/

IBM Releases Novel AI-Powered Technologies to Help Health and Research Community Accelerate the Discovery of Medical Insights and Treatments for COVID-19

April 3, 2020 | Written by: 

IBM Research has been actively developing new cloud and AI-powered technologies that can help researchers across a variety of scientific disciplines accelerate the process of discovery. As the COVID-19 pandemic unfolds, we continue to ask how these technologies and our scientific knowledge can help in the global battle against coronavirus.

Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.

Though some of the resources are still in exploratory stages, IBM is making them available to qualifying researchers at no charge to aid the international scientific investigation of COVID-19.

Today’s announcement follows our recent leadership in launching the U.S. COVID-19 High Performance Computing Consortium, which is harnessing massive computing power in the effort to help confront the coronavirus.

Streamlining the Search for Information

Healthcare agencies and governments around the world have quickly amassed medical and other relevant data about the pandemic. And, there are already vast troves of medical research that could prove relevant to COVID-19. Yet, as with any large volume of disparate data sources, it is difficult to efficiently aggregate and analyze that data in ways that can yield scientific insights.

To help researchers access structured and unstructured data quickly, we are offering a cloud-based AI research resource that has been trained on a corpus of thousands of scientific papers contained in the COVID-19 Open Research Dataset (CORD-19), prepared by the White House and a coalition of research groups, and licensed databases from the DrugBankClinicaltrials.gov and GenBank. This tool uses our advanced AI and allows researchers to pose specific queries to the collections of papers and to extract critical COVID-19 knowledge quickly. Please note, access to this resource will be granted only to qualified researchers. To learn more and request access, please click here.

Aiding the Hunt for Treatments

The traditional drug discovery pipeline relies on a library of compounds that are screened, improved, and tested to determine safety and efficacy. In dealing with new pathogens such as SARS-CoV-2, there is the potential to enhance the compound libraries with additional novel compounds. To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials.

We have applied this AI technology against three COVID-19 targets to identify 3,000 new small molecules as potential COVID-19 therapeutic candidates. IBM is releasing these molecules under an open license, and researchers can study them via a new interactive molecular explorer tool to understand their characteristics and relationship to COVID-19 and identify candidates that might have desirable properties to be further pursued in drug development.

To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic. Built to discover the molecular features in viral and bacterial genomes, this cloud-based repository and research tool includes genes, proteins and other molecular targets from sequenced viral and bacterial organisms in one place with connections pre-computed to help accelerate discovery of molecular targets required for drug design, test development and treatment.

Select IBM collaborators from government agencies, academic institutions and other organizations already use this platform for bacterial genomic study. And now, those working on COVID-19 can request the IBM Functional Genomics Platform interface to explore the genomic features of the virus. Access to the IBM Functional Genomics Platform will be prioritized for those conducting COVID-19 research. To learn more and request access, please click here.

Drug and Disease Information

Clinicians and healthcare professionals on the frontlines of care will also have free access to hundreds of pieces of evidence-based, curated COVID-19 and infectious disease content from IBM Micromedex and EBSCO DynaMed. Using these two rich decision support solutions, users will have access to drug and disease information in a single and comprehensive search. Clinicians can also provide patients with consumer-friendly patient education handouts with relevant, actionable medical information. IBM Micromedex is one of the largest online reference databases for medication information and is used by more than 4,500 hospitals and health systems worldwide. EBSCO DynaMed provides peer-reviewed clinical content, including systematic literature reviews in 28 specialties for comprehensive disease topics, health conditions and abnormal findings, to highly focused topics on evaluation, differential diagnosis and management.

The scientific community is working hard to make important new discoveries relevant to the treatment of COVID-19, and we’re hopeful that releasing these novel tools will help accelerate this global effort. This work also outlines our long-term vision for the future of accelerated discovery, where multi-disciplinary scientists and clinicians work together to rapidly and effectively create next generation therapeutics, aided by novel AI-powered technologies.

Learn more about IBM’s response to COVID-19: IBM.com/COVID19.

Source: https://www.ibm.com/blogs/research/2020/04/ai-powered-technologies-accelerate-discovery-covid-19/

DiA Imaging Analysis Receives Grant to Accelerate Global Access to its AI Ultrasound Solutions in the Fight Against COVID-19

Source: https://www.grantnews.com/news-articles/?rkey=20200512UN05506&filter=12337

Grant will allow company to accelerate access to its AI solutions and use of ultrasound in COVID-19 emergency settings

TEL AVIV, IsraelMay 12, 2020 /PRNewswire-PRWeb/ — DiA Imaging Analysis, a leading provider of AI based ultrasound analysis solutions, today announced that it has received a government grant from the Israel Innovation Authority (IIA) to develop solutions for ultrasound imaging analysis of COVID-19 patients using Artificial Intelligence (AI).Using ultrasound in point of care emergency settings has gained momentum since the outbreak of COVID-19 pandemic. In these settings, which include makeshift hospital COVID-19 departments and triage “tents,” portable ultrasound offers clinicians diagnostic decision support, with the added advantage of being easier to disinfect and eliminating the need to transport patients from one room to another.However, analyzing ultrasound images is a process that it is still mostly done visually, leading to a growing market need for automated solutions and decision support.As the leading provider of AI solutions for ultrasound analysis and backed by Connecticut Innovations, DiA makes ultrasound analysis smarter and accessible to both new and expert ultrasound users with various levels of experience. The company’s flagship LVivo Cardio Toolbox for AI-based cardiac ultrasound analysis enables clinicians to automatically generate objective clinical analysis, with increased accuracy and efficiency to support decisions about patient treatment and care.

The IIA grant provides a budget of millions NIS to increase access to DiA’s solutions for users in Israel and globally, and accelerate R&D with a focus on new AI solutions for COVID-19 patient management. DiA solutions are vendor-neutral and platform agnostic, as well as powered to run in low processing, mobile environments like handheld ultrasound.Recent data highlights the importance of looking at the heart during the progression of COVID-19, with one study citing 20% of patients hospitalized with COVID-19 showing signs of heart damage and increased mortality rates in those patients. DiA’s LVivo cardiac analysis solutions automatically generate objective, quantified cardiac ultrasound results to enable point-of-care clinicians to assess cardiac function on the spot, near patients’ bedside.

According to Dr. Ami Applebaum, the Chairman of the Board of the IIA, “The purpose of IIA’s call was to bring solutions to global markets for fighting COVID-19, with an emphasis on relevancy, fast time to market and collaborations promising continuity of the Israeli economy. DiA meets these requirements with AI innovation for ultrasound.”DiA has received several FDA/CE clearances and established distribution partnerships with industry leading companies including GE Healthcare, IBM Watson and Konica Minolta, currently serving thousands of end users worldwide.”We see growing use of ultrasound in point of care settings, and an urgent need for automated, objective solutions that provide decision support in real time,” said Hila Goldman-Aslan, CEO and Co-founder of DiA Imaging Analysis, “Our AI solutions meet this need by immediately helping clinicians on the frontlines to quickly and easily assess COVID-19 patients’ hearts to help guide care delivery.”

About DiA Imaging Analysis:
DiA Imaging Analysis provides advanced AI-based ultrasound analysis technology that makes ultrasound accessible to all. DiA’s automated tools deliver fast and accurate clinical indications to support the decision-making process and offer better patient care. DiA’s AI-based technology uses advanced pattern recognition and machine-learning algorithms to automatically imitate the way the human eye detects image borders and identifies motion. Using DiA’s tools provides automated and objective AI tools, helps reduce variability among users, and increases efficiency. It allows clinicians with various levels of experience to quickly and easily analyze ultrasound images.

For additional information, please visit http://www.dia-analysis.com.

Read Full Post »


2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Dialogue among principals is a World Forum’s signature. Expert moderators guiding discussion and questions in audience friendly exchanges. No slides – shared perspectives facilitated by Harvard faculty, leading journalists and Mass General Brigham executives.

Jeffrey Golden, MD

Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Hadine Joffe, MD

Vice Chair, Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, Harvard Medical School

Thomas Sequist, MD

Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, Harvard Medical School

Erica Shenoy, MD, PhD

Associate Chief, Infection Control Unit, MGH; Assistant Professor, Harvard Medical School

Gregg Meyer, MD

Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor, Harvard Medical School

Ravi Thadhani, MD

CAO, Mass General Brigham; Professor and Faculty Dean for Academic Programs, Harvard Medical School

Ann Prestipino

SVP; Incident Commander, MGH

Roger Kitterman

VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

David Louis, MD

Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, Harvard Medical School

Janet Wu

Bloomberg

Ron Walls, MD

EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Alice Park

Senior Writer, TIME

 

Jeffrey Golden, MD

Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Hadine Joffe, MD

Vice Chair, Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, Harvard Medical School

Thomas Sequist, MD

Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, Harvard Medical School

Erica Shenoy, MD, PhD

Associate Chief, Infection Control Unit, MGH; Assistant Professor, Harvard Medical School

Gregg Meyer, MD

Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor, Harvard Medical School

Ravi Thadhani, MD

CAO, Mass General Brigham; Professor and Faculty Dean for Academic Programs, Harvard Medical School

Ann Prestipino

SVP; Incident Commander, MGH

Roger Kitterman

VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

David Louis, MD

Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, Harvard Medical School

Janet Wu

Bloomberg

Ron Walls, MD

EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Alice Park

Senior Writer, TIME

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

 

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »

Older Posts »